Drug intelligence / Profile preview

5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione

Development stage: Unknown
Modality: Small Molecules

Overview

5-Heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione is a synthetic small molecule with the formula C14H17NO3S and a molecular weight of approximately 279.36 g/mol. It is classified as an organooxygen compound within the carbonyl compounds subclass. The compound has been listed in chemical and pharmaceutical databases (e.g., DrugBank DB07636) as an experimental agent but has not been approved for any medical indication or entered clinical trials. No detailed mechanism of action or therapeutic use has been established for this molecule[1][2][9].

Other names: 5-heptyl-4-hydroxy-6,7-dihydro-1,3-benzothiazole-6,7-dione5-n-heptyl-6-hydroxy-4,7-dioxobenzothiazole611207-02-4

Beyond the preview

Go deeper on 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione.

Explore the full profile